|
USA-UT-MORRILTON Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Early initiation of ambroxol treatment diminishes neurological . . .
Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings Eur J Paediatr Neurol 2021 May;32:66-72 Epub 2021 Mar 31 PubMed Recommends Please login to recommend the paper Comments No Available Comments Make a Comment To make a comment you must login or
- Large Phase 2 Trial Starting Up in Genetic Parkinson’s Population
In recent years, a growing number of companies have started to look for ways to stem the progression of Parkinson’s disease One approach targets glucocerebrosidase (GBA), the leading genetic risk factor for sporadic PD and dementia with Lewy bodies (DLB) Defects in this lysosomal enzyme cause a
- LTI-291 - ALZFORUM
Overview Name: LTI-291 Therapy Type: Small Molecule Target Type: Other Condition(s): Parkinson's Disease U S FDA Status: Parkinson's Disease (Phase 2) Company: Lysosomal Therapeutics Inc
- Therapeutics Search - ALZFORUM
Ambroxol: Ambrosan, Mucosolvan: Parkinson's Disease (Phase 2), Parkinson's Disease Dementia (Phase 2), Dementia with Lewy Bodies (Phase 2) alpha-synuclein, Other: Small Molecule: Amilomotide: CAD106: Alzheimer's Disease (Inactive) Novartis Pharmaceuticals Corporation: Amyloid-Related: Immunotherapy (active) None: AN-1792: AIP 001: Alzheimer's
- Therapeutics Search | ALZFORUM
Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24 060 ACI-3024 ACI-7104 056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AIT-101 AKST4290 AL002 AL003 AL044 AL101 ALIA-1758 Allopregnanolone Alpha
- Therapeutics Search | ALZFORUM
Ambroxol: Ambrosan, Mucosolvan: Parkinson's Disease (Phase 2), Parkinson's Disease Dementia (Phase 2), Dementia with Lewy Bodies (Phase 2) alpha-synuclein, Other: Small Molecule: ANX005: Amyotrophic Lateral Sclerosis (Phase 2) Annexon, Inc Inflammation, Other: Immunotherapy (passive) Apabetalone: RVX208, RVX000222: MCI-VaD (Phase 3
- Therapeutics | ALZFORUM
Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24 060 ACI-3024 ACI-7104 056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AIT-101 AKST4290 AL002 AL003 AL044 AL101 ALIA-1758 Allopregnanolone Alpha-Tocopherol ALX-001 ALZ-101 ALZ-801 Alzhemed™ ALZT-OP1
- Therapeutics Search - ALZFORUM
Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24 060 ACI-3024 ACI-35 ACI-7104 056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AIT-101 AKST4290 AL002 AL003 AL044 AL101 ALIA-1758 Allopregnanolone ALPHA-1062 Alpha-Tocopherol ALX-001 ALZ-101 ALZ-801
- Therapeutics Search | ALZFORUM
Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24 060 ACI-3024 ACI-35 ACI-7104 056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AKST4290 AL002 AL003 AL044 AL101 Allopregnanolone ALN-APP ALPHA-1062 Alpha-Tocopherol ALX-001 ALZ-101 ALZ-801
|
|